Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel Free ALUR Stock Alerts

Allurion Technologies (ALUR) Competitors

Allurion Technologies logo
$0.70 -0.10 (-12.49%)
As of 05/13/2026 02:25 PM Eastern
Compare

ALUR vs. TELA, NTRB, PSTV, NMTC, and AGPU

Should you buy Allurion Technologies stock or one of its competitors? MarketBeat compares Allurion Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Allurion Technologies include TELA Bio (TELA), Nutriband (NTRB), Plus Therapeutics (PSTV), NeuroOne Medical Technologies (NMTC), and Predictive Oncology (AGPU). These companies are all part of the "medical equipment" industry.

How does Allurion Technologies compare to TELA Bio?

TELA Bio (NASDAQ:TELA) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

94.4% of TELA Bio shares are held by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are held by institutional investors. 4.7% of TELA Bio shares are held by insiders. Comparatively, 8.1% of Allurion Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

TELA Bio presently has a consensus price target of $2.20, suggesting a potential upside of 129.17%. Allurion Technologies has a consensus price target of $3.00, suggesting a potential upside of 328.57%. Given Allurion Technologies' higher possible upside, analysts plainly believe Allurion Technologies is more favorable than TELA Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TELA Bio
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Allurion Technologies
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Allurion Technologies has lower revenue, but higher earnings than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TELA Bio$80.28M0.54-$38.83M-$0.83N/A
Allurion Technologies$17.21M0.61-$7.20M-$10.56N/A

TELA Bio has a net margin of -49.30% compared to Allurion Technologies' net margin of -199.96%. Allurion Technologies' return on equity of 0.00% beat TELA Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
TELA Bio-49.30% -688.50% -55.77%
Allurion Technologies -199.96%N/A -77.13%

TELA Bio has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market. Comparatively, Allurion Technologies has a beta of -0.18, meaning that its stock price is 118% less volatile than the broader market.

In the previous week, TELA Bio had 7 more articles in the media than Allurion Technologies. MarketBeat recorded 9 mentions for TELA Bio and 2 mentions for Allurion Technologies. Allurion Technologies' average media sentiment score of 0.00 beat TELA Bio's score of -0.13 indicating that Allurion Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TELA Bio
1 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Allurion Technologies
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

TELA Bio beats Allurion Technologies on 9 of the 16 factors compared between the two stocks.

How does Allurion Technologies compare to Nutriband?

Allurion Technologies (NYSE:ALUR) and Nutriband (NASDAQ:NTRB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

Allurion Technologies has higher revenue and earnings than Nutriband. Nutriband is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allurion Technologies$17.21M0.61-$7.20M-$10.56N/A
Nutriband$2.04M20.86-$8.23M-$2.60N/A

Allurion Technologies has a net margin of -199.96% compared to Nutriband's net margin of -403.98%. Allurion Technologies' return on equity of 0.00% beat Nutriband's return on equity.

Company Net Margins Return on Equity Return on Assets
Allurion Technologies-199.96% N/A -77.13%
Nutriband -403.98%-118.33%-101.92%

21.4% of Allurion Technologies shares are owned by institutional investors. Comparatively, 19.7% of Nutriband shares are owned by institutional investors. 8.1% of Allurion Technologies shares are owned by company insiders. Comparatively, 52.2% of Nutriband shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Allurion Technologies had 1 more articles in the media than Nutriband. MarketBeat recorded 2 mentions for Allurion Technologies and 1 mentions for Nutriband. Nutriband's average media sentiment score of 1.87 beat Allurion Technologies' score of 0.00 indicating that Nutriband is being referred to more favorably in the news media.

Company Overall Sentiment
Allurion Technologies Neutral
Nutriband Very Positive

Allurion Technologies has a beta of -0.18, suggesting that its share price is 118% less volatile than the broader market. Comparatively, Nutriband has a beta of 1.96, suggesting that its share price is 96% more volatile than the broader market.

Allurion Technologies currently has a consensus price target of $3.00, indicating a potential upside of 328.57%. Given Allurion Technologies' stronger consensus rating and higher possible upside, research analysts plainly believe Allurion Technologies is more favorable than Nutriband.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Allurion Technologies
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Nutriband
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Summary

Allurion Technologies beats Nutriband on 11 of the 16 factors compared between the two stocks.

How does Allurion Technologies compare to Plus Therapeutics?

Plus Therapeutics (NASDAQ:PSTV) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

Allurion Technologies has a net margin of -199.96% compared to Plus Therapeutics' net margin of -429.43%.

Company Net Margins Return on Equity Return on Assets
Plus Therapeutics-429.43% N/A -92.28%
Allurion Technologies -199.96%N/A -77.13%

Allurion Technologies has higher revenue and earnings than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Plus Therapeutics$5.21M7.51-$22.39M-$31.00N/A
Allurion Technologies$17.21M0.61-$7.20M-$10.56N/A

3.3% of Plus Therapeutics shares are owned by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are owned by institutional investors. 2.5% of Plus Therapeutics shares are owned by company insiders. Comparatively, 8.1% of Allurion Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Plus Therapeutics had 3 more articles in the media than Allurion Technologies. MarketBeat recorded 5 mentions for Plus Therapeutics and 2 mentions for Allurion Technologies. Plus Therapeutics' average media sentiment score of 1.06 beat Allurion Technologies' score of 0.00 indicating that Plus Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Plus Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Allurion Technologies
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Plus Therapeutics presently has a consensus price target of $58.00, indicating a potential upside of 917.54%. Allurion Technologies has a consensus price target of $3.00, indicating a potential upside of 328.57%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Plus Therapeutics is more favorable than Allurion Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Plus Therapeutics
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43
Allurion Technologies
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Plus Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Allurion Technologies has a beta of -0.18, indicating that its stock price is 118% less volatile than the broader market.

Summary

Allurion Technologies beats Plus Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Allurion Technologies compare to NeuroOne Medical Technologies?

NeuroOne Medical Technologies (NASDAQ:NMTC) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

16.1% of NeuroOne Medical Technologies shares are held by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are held by institutional investors. 11.8% of NeuroOne Medical Technologies shares are held by company insiders. Comparatively, 8.1% of Allurion Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, NeuroOne Medical Technologies had 5 more articles in the media than Allurion Technologies. MarketBeat recorded 7 mentions for NeuroOne Medical Technologies and 2 mentions for Allurion Technologies. Allurion Technologies' average media sentiment score of 0.00 beat NeuroOne Medical Technologies' score of -0.12 indicating that Allurion Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NeuroOne Medical Technologies
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Allurion Technologies
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

NeuroOne Medical Technologies has higher earnings, but lower revenue than Allurion Technologies. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeuroOne Medical Technologies$12.10M3.14-$3.61M-$1.02N/A
Allurion Technologies$17.21M0.61-$7.20M-$10.56N/A

NeuroOne Medical Technologies has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, Allurion Technologies has a beta of -0.18, meaning that its share price is 118% less volatile than the broader market.

NeuroOne Medical Technologies has a net margin of -68.35% compared to Allurion Technologies' net margin of -199.96%. Allurion Technologies' return on equity of 0.00% beat NeuroOne Medical Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
NeuroOne Medical Technologies-68.35% -92.06% -66.04%
Allurion Technologies -199.96%N/A -77.13%

NeuroOne Medical Technologies presently has a consensus price target of $11.67, suggesting a potential upside of 158.68%. Allurion Technologies has a consensus price target of $3.00, suggesting a potential upside of 328.57%. Given Allurion Technologies' higher probable upside, analysts plainly believe Allurion Technologies is more favorable than NeuroOne Medical Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeuroOne Medical Technologies
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Allurion Technologies
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

NeuroOne Medical Technologies beats Allurion Technologies on 10 of the 16 factors compared between the two stocks.

How does Allurion Technologies compare to Predictive Oncology?

Predictive Oncology (NASDAQ:AGPU) and Allurion Technologies (NYSE:ALUR) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Allurion Technologies has a consensus price target of $3.00, indicating a potential upside of 328.57%. Given Allurion Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Allurion Technologies is more favorable than Predictive Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Predictive Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Allurion Technologies
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Allurion Technologies has a net margin of -199.96% compared to Predictive Oncology's net margin of -185,476.72%.

Company Net Margins Return on Equity Return on Assets
Predictive Oncology-185,476.72% N/A -970.41%
Allurion Technologies -199.96%N/A -77.13%

Allurion Technologies has higher revenue and earnings than Predictive Oncology. Predictive Oncology is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Predictive Oncology$120K299.16-$233.10M-$12.62N/A
Allurion Technologies$17.21M0.61-$7.20M-$10.56N/A

9.0% of Predictive Oncology shares are owned by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are owned by institutional investors. 1.2% of Predictive Oncology shares are owned by insiders. Comparatively, 8.1% of Allurion Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Predictive Oncology and Predictive Oncology both had 2 articles in the media. Predictive Oncology's average media sentiment score of 0.93 beat Allurion Technologies' score of 0.00 indicating that Predictive Oncology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Predictive Oncology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Allurion Technologies
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Predictive Oncology has a beta of 3.45, indicating that its share price is 245% more volatile than the broader market. Comparatively, Allurion Technologies has a beta of -0.18, indicating that its share price is 118% less volatile than the broader market.

Summary

Allurion Technologies beats Predictive Oncology on 11 of the 14 factors compared between the two stocks.

Get Allurion Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALUR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALUR vs. The Competition

Export
MetricAllurion TechnologiesMED PRODUCTS IndustryMedical SectorNYSE Exchange
Market Cap$10.50M$8.12B$6.30B$22.96B
Dividend YieldN/A2.50%2.79%4.07%
P/E Ratio-0.0718.1921.0328.29
Price / Sales0.617.65552.9824.48
Price / CashN/A16.7642.9425.11
Price / Book-0.023.759.824.73
Net Income-$7.20M$223.05M$3.55B$1.07B
7 Day Performance4.48%-2.05%-0.53%-1.11%
1 Month Performance-16.69%3.40%1.20%1.36%
1 Year Performance-77.12%1.89%41.23%24.41%

Allurion Technologies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALUR
Allurion Technologies
1.3219 of 5 stars		$0.70
-12.5%		$3.00
+328.6%		-70.7%$10.50M$17.21MN/A501
TELA
TELA Bio
2.88 of 5 stars		$1.02
+5.1%		$2.20
+115.7%		-2.0%$45.67M$80.28MN/A120
NTRB
Nutriband
0.6104 of 5 stars		$3.66
+0.3%		N/A-38.9%$44.49M$2.04MN/A10
PSTV
Plus Therapeutics
3.0325 of 5 stars		$5.85
-3.1%		$58.00
+891.5%		-67.3%$40.13M$5.21MN/A20
NMTC
NeuroOne Medical Technologies
3.9247 of 5 stars		$4.39
+1.4%		$13.50
+207.5%		+16.7%$36.96M$12.10MN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:ALUR) was last updated on 5/14/2026 by MarketBeat.com Staff.
From Our Partners
Is this AI lab Elon’s SpaceX lifeline?
Elon Musk went from calling one AI lab 'evil' to striking a deal giving it access to SpaceX's entire Colossus ...
Chaikin Analytics | Sponsoredtc pixel
The one number Musk can't hide in the S-1
When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requi...
Behind the Markets | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Collect $1,170 a month from silver
I've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...
Investors Alley | Sponsoredtc pixel
The system holding the dollar together is gone…
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel
SpaceX IPO Warning: Before you buy any SpaceX shares, read this.
The SpaceX IPO is valued at $1.75 trillion - but buying shares directly may not be the strongest play availabl...
Weiss Ratings | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel